Discover 15 paid clinical trials in Cheyenne, Wyoming. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 15
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
for
Glaucoma, Open-Angle, Ocular Hypertension
Location: Cheyenne WY, Newport Beach CA, Houston TX, Petaluma CA,
Sponsor: Amneal Pharmaceuticals, LLC
Sex: All
Age: 18+
Code: NCT05401357
Phase3, Recruiting
Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Navigation and Parent Peer Support to Promote Access
for
Mental Disorder, Child, Mental Health, Family Health
Location: Cheyenne WY, Aurora CO, Pittsburgh PA
Sponsor: University of Colorado, Denver
Sex: All
Age: 1 - 70+
Code: NCT04029220
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
By submitting, you consent to the use of your personal details, including contact information and location, to respond to your request for information related to clinical trials, as outlined in the Privacy Policy. If at any time you want to discontinue receiving alerts, please click the Unsubscribe link in the email received.
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
for
Chronic Granulomatous Disease (CGD)
Location: Cheyenne WY, Denver CO, Pierre SD, Salt Lake City UT,
Sponsor: Ensoma
Sex: All
Age: 0 - 70+
Code: NCT06605378
Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases